What is the recommended treatment for intestinal swelling?

Treatment of Intestinal Swelling

For inflammatory bowel disease causing intestinal swelling, start with oral prednisolone 40 mg daily for moderate-to-severe disease, or high-dose mesalazine 4 g daily for mild disease, with treatment selection based on disease severity, location, and pattern. 1

Initial Assessment and Disease Characterization

Before initiating treatment, confirm active inflammation through objective measures rather than symptoms alone. Use C-reactive protein, fecal calprotectin, ileocolonoscopy, or imaging (CT, MR enterography, or intestinal ultrasound) to document inflammation 2. Consider disease location (ileal, ileocolonic, colonic), pattern (inflammatory, stricturing, fistulating), and exclude alternative causes like bacterial overgrowth, bile salt malabsorption, or fibrotic strictures 1.

Treatment Algorithm by Disease Severity

Mild Ileocolonic Disease

• Start with high-dose mesalazine 4 g daily as initial therapy 1
• This approach has Grade A evidence for mild inflammatory Crohn's disease

Moderate-to-Severe Disease

• Initiate oral prednisolone 40 mg daily for patients with moderate-to-severe disease or those failing mesalazine 1
• Taper gradually over 8 weeks based on severity and response; rapid reduction increases early relapse risk 1
• For isolated ileo-caecal disease with moderate activity, budesonide 9 mg daily is an alternative, though marginally less effective than prednisolone 1

Severe Disease Requiring Hospitalization

• Use intravenous steroids: hydrocortisone 400 mg/day or methylprednisolone 60 mg/day 1
• Add concomitant IV metronidazole to distinguish active disease from septic complications 1
• Manage jointly with gastroenterology and colorectal surgery 1
• Monitor pulse, stool frequency, C-reactive protein, and obtain plain abdominal radiographs to identify patients needing colectomy 1

Advanced Therapy Selection (When Steroids Fail or for Steroid-Sparing)

For patients failing corticosteroids within 2 weeks, unable to taper successfully, or requiring repeated courses, initiate advanced therapy 3. The 2025 AGA guidelines provide clear positioning:

Higher Efficacy Options (Strong Recommendation)

Use infliximab, adalimumab, ustekinumab, risankizumab, mirikizumab, guselkumab, or upadacitinib over no treatment 2. These have moderate-to-high certainty evidence and absolute efficacy differences ≥5% compared to lower efficacy therapies.

Moderate Efficacy Options (Conditional Recommendation)

Consider certolizumab pegol or vedolizumab when higher efficacy options are contraindicated or unavailable 2.

Immunomodulator Adjuncts

• Azathioprine 1.5-2.5 mg/kg/day or mercaptopurine 0.75-1.5 mg/kg/day serve as steroid-sparing agents but have slow onset, precluding use as sole therapy 1
• Check FBC within 4 weeks of starting and every 6-12 weeks thereafter to monitor for neutropenia 1

Adjunctive Nutritional Support

• Elemental or polymeric diets are less effective than corticosteroids but appropriate for patients with contraindications to steroids or those preferring to avoid them 1
• Total parenteral nutrition is appropriate adjunctive therapy in complex fistulating disease 1
• Provide nutritional support (enteral or parenteral) if the patient is malnourished 1

Critical Pitfalls to Avoid

1. Do not use infliximab in patients with obstructive symptoms from intestinal swelling, as it may worsen obstruction 1
2. Avoid rapid steroid tapers (faster than 8 weeks), which increase early relapse rates 1
3. Do not use corticosteroids for long-term maintenance—they are ineffective and harmful for this purpose 1, 3
4. Screen for hepatitis B and tuberculosis before starting advanced therapies to prevent reactivation 2
5. Distinguish functional symptoms from active inflammation before escalating therapy, as up to one-third of patients have concomitant functional symptoms 2

Special Considerations

For ulcerative colitis specifically causing intestinal swelling, prednisolone combined with 5-ASA is recommended for moderate-to-severe disease 3. Maintenance therapy with aminosalicylates, azathioprine, or mercaptopurine reduces relapse risk 1.

For fistulating disease with swelling, metronidazole 400 mg three times daily and/or ciprofloxacin 500 mg twice daily are first-line for simple perianal fistulae 1. Reserve infliximab (three infusions of 5 mg/kg at 0,2, and 6 weeks) for refractory cases as part of a strategy including immunomodulation and surgery 1.

Surgery should be considered for patients failing medical therapy or as primary therapy in limited ileal/ileo-caecal disease 1. Severe ulcerative colitis carries a 25-30% chance of requiring colectomy 1.